Novartis plans bird flu vaccine plant in U.S.

05/10/2006 | MarketWatch

Novartis plans to build a vaccine plant in the U.S. that incorporates cell-based production technologies to produce avian flu vaccine quickly in case of a pandemic. Novartis CEO Daniel Vasella said the plant could cost around $400 million and may not be in production for several years. Announcement of its location could come in a few weeks, he said.

View Full Article in:

MarketWatch

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA